Skip Navigation
Megan McArdle

Megan McArdle - Megan McArdle is a senior editor for The Atlantic who writes about business and economics. She has worked at three start-ups, a consulting firm, an investment bank, a disaster recovery firm at Ground Zero, and The Economist. More

Megan was born and raised on the Upper West Side of Manhattan, and yes, she does enjoy her lattes, as well as the occasional extra-dry skim-milk cappuccino. Her checkered work history includes three start-ups, four years as a technology project manager for a boutique consulting firm, a summer as an associate at an investment bank, and a year spent as sort of an executive copy girl for one of the disaster-recovery firms at Ground Zero … all before the age of 30.

While working at Ground Zero, Megan started Live From the WTC, a blog focused on economics, business, and cooking. She may or may not have been the first major economics blogger, depending on whether we are allowed to throw outlying variables such as Brad Delong out of the set. From there it was but a few steps down the slippery slope to freelance journalism. She has worked in various capacities for The Economist, where she wrote about economics and oversaw the founding of Free Exchange, the magazine's economics blog. She has also maintained her own blog, Asymmetrical Information, which moved to The Atlantic, along with its owner, in August 2007.

Megan holds a bachelor's degree in English literature from the University of Pennsylvania and an M.B.A. from the University of Chicago. After a lifetime as a New Yorker, she now resides in northwest Washington, D.C., where she is still trying to figure out what one does with an apartment larger than 400 square feet.

No perfect world

By Megan McArdle
Apr 11 2008, 11:07 AM ET Comment

Pharmaceuticals really are marvelous things. They're responsible for most of the increases in life expectancy that took place in the 20th century, and believe it or not, even with rising drug costs they save us money by replacing more expensive treatments like surgery. Saving money is nice, of course, and so is the extra economic growth we have from keeping more productive people around. But the really great thing is the number of active life years it adds to the world--active life expectancy is actually increasing faster than ordinary life expectancy in the US.

Unfortunately, no cloud is without its silver lining. In the case of pharmaceuticals, it's the fact that some small number of the people who take them will thereby be made worse off. The regulatory and liability systems try to control that, but as Derek Lowe points out, they can't fix everything:

This illustrates why either extreme of that argument is untenable. On the make-‘em-pay side, you have trial lawyers arguing that if companies just wouldn’t put defective products on the market, well, they wouldn’t have anything to worry about, would they? Test your drugs correctly and things will be fine! But Exubera’s pre-approval life was as long and detailed as could be. The testing went on and on – and after all, insulin itself has been on the market for more than half a century. What more would a company need to say something is safe?

Then there’s the other side – total pre-emption, which says that the FDA is there to regulate and sign off on safety and efficacy, and by gosh we should have them do it. Once this mighty agency gives its stamp of approval, that settles it. But again, the FDA put Exubera through all kinds of paces. If every drug took that long and cost that much to develop, we’d be in even worse shape than we are now, believe me. So what’s the agency to do?

The truth, as far as I can see, is that no one can guarantee the safety of a new drug. If you want to take that further, guaranteeing the safety of an existing drug isn’t possible, either. Every known drug is capable of causing trouble at some dose, and every known drug is capable of causing trouble at its normal dose in some people. Every new drug has the possibility of doing things no one ever anticipated, once it gets into enough patients for enough time. Every single one.

Complete safety doesn’t exist, and never has. You can have more safety, if you’re willing to take enough time and spend enough money. But you can take all the time we have on earth, and spend all the money available, and you still won’t be able to promise that nothing bad will ever happen. Pretending that either the drug companies or the regulatory agencies can make that fact go away is a position for fools and demagogues.

Libertarians tend to chafe at the notion that companies should be liable for something they couldn't predict. On the other hand, neither could the person who took the drug--why should they bear all the costs? Liability, in theory, pretty effectively socializes the risk of something that has great public benefits.

The problem, of course, is that juries aren't particularly well equipped to handle scientific arguments. Liability as a solution for medical disasters errs both ways--it often fails to punish the guilty, and does snare the innocent (see Breast Implants, class actions against). The liability system evolved during an era in which most problems were basically comprehensible to the average juror. Now with things like environmental pollutants, construction safety standards, medical malpractice, pharmaceutical liability, and securities law, jurors are dealing with things that take advanced degrees (or the work experience equivalent) to understand.

I don't know what the solution is; perhaps we should push the VICAP model more widely for pharma risk in cases where the side effects were simply unpredictable. But that has its own problems.



Presented by

More at The Atlantic

A Short Animated Biography of tHOMAS Edison The Life of Thomas Edison, Animated
The fEARLESSness of Jeremy Lin The Fearlessness of Jeremy Lin
What Matters in President Obama's 2013 Budget What Matters in President Obama's 2013 Budget
'Plug In Better': A Manifesto Plug In Better
The GOP Primary Is Badly Wounding Mitt Romney Why a Long Primary Fight Will Hurt Mitt Romney

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register.
blog comments powered by Disqus
Special Report
The Civil War National Portrait Gallery The Civil War
A 150th-anniversary commemorative issue, with Atlantic work by Mark Twain, Harriet Beecher Stowe, Frederick Douglass, and others. Read more ›
View All Correspondents

The Biggest Story in Photos

Valentine's Day 2012

Feb 14, 2012

Subscribe Now

SAVE 59%! 10 issues JUST $2.45 PER COPY

Facebook

Newsletters

Sign up to receive our free newsletters

(sample)

(sample)

(sample)

(sample)

Megan McArdle
from the Magazine

Why Companies Fail

GM’s stock price has sunk by a third since its IPO. Why is corporate turnaround so difficult…

The Graduates

Busted banking careers, crashed consultants, and shrunken incomes: the author attends her 10-year…

Romney’s Business

The Republican contender touts his business experience—but does it really matter?